泽璟制药：盐酸吉卡昔替尼片治疗活动性强直性脊柱炎的III期临床试验达到主要疗效终点

Core Viewpoint - Zejing Pharmaceutical (688266.SH) announced that its self-developed Class 1 new drug, Jikaxitinib Hydrochloride Tablets (formerly known as Jackatinib Tablets), has achieved the primary efficacy endpoint in a Phase III clinical trial for treating active ankylosing spondylitis, demonstrating statistical significance (p<0.0001) [1] Group 1 - The Phase III clinical trial titled "Efficacy and Safety of Jikaxitinib Hydrochloride Tablets in Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study" has met its primary efficacy endpoint [1] - The company plans to accelerate the market launch process for Jikaxitinib Hydrochloride Tablets for the indication of active ankylosing spondylitis [1]